X4 Pharmaceuticals Inc (XFOR) concluded trading on Wednesday at a closing price of $0.74, with 36.64 million shares of worth about $27.11 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -15.04% during that period and on January 29, 2025 the price saw a gain of about 52.59%. Currently the company’s common shares owned by public are about 168.51M shares, out of which, 117.85M shares are available for trading.
Stock saw a price change of 50.69% in past 5 days and over the past one month there was a price change of -8.75%. Year-to-date (YTD), XFOR shares are showing a performance of 0.22% which decreased to -5.11% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.26 but also hit the highest price of $1.60 during that period. The average intraday trading volume for X4 Pharmaceuticals Inc shares is 3.84 million. The stock is currently trading 24.44% above its 20-day simple moving average (SMA20), while that difference is up 35.95% for SMA50 and it goes to 1.17% higher than SMA200.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) currently have 168.51M outstanding shares and institutions hold larger chunk of about 35.68% of that.
The stock has a current market capitalization of $125.39M and its 3Y-monthly beta is at 0.08. It has posted earnings per share of -$0.09 in the same period. It has Quick Ratio of 4.80 while making debt-to-equity ratio of 1.31. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for XFOR, volatility over the week remained 25.40% while standing at 16.92% over the month.
Analysts are in expectations that X4 Pharmaceuticals Inc (XFOR) stock would likely to be making an EPS of -0.16 in the current quarter, while forecast for next quarter EPS is -0.15 and it is -0.6 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.17 which is -0.13 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.1 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 76.02% while it is estimated to decrease by -312.19% in next year. EPS is likely to shrink at an annualized rate of 14.52% for next 5-years, compared to annual growth of 73.95% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley Securities on December 12, 2023 offering a Neutral rating for the stock and assigned a target price range of between $3 and $1 to it. Coverage by B. Riley Securities stated X4 Pharmaceuticals Inc (XFOR) stock as a Buy in their note to investors on August 30, 2023, suggesting a price target of $3 for the stock. On December 22, 2022, Cantor Fitzgerald Initiated their recommendations, while on December 12, 2022, Piper Sandler Initiated their ratings for the stock with a price target of $3. Stock get an Outperform rating from Oppenheimer on December 23, 2019.
